We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
Read MoreHide Full Article
Shares of Syros Pharmaceuticals (SYRS - Free Report) plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, tamibarotene, for treating higher-risk myelodysplastic syndrome (HR-MDS) failed to meet the primary endpoint of complete response (CR) rate. Tamibarotene is Syros’ proprietary, oral, selective RARα agonist.
The phase III SELECT-MDS-1 study evaluated tamibarotene in combination with azacitidine, a chemotherapy, in newly diagnosed HR-MDS patients with RARα gene overexpression. Per the data readout, the CR rate in the first 190 enrolled patients in the tamibarotene/azacitidine treatment arm was 23.8%, which failed to demonstrate statistical significance over the CR rate of 18.8% observed in the placebo/azacitidine control arm.
However, Syros reported that the combo drug was well-tolerated by the total enrolled HR-MDS patient population in the SELECT-MDS-1 study. Moreover, the treatment-related adverse events were similar to those observed in earlier company-sponsored studies.
Year to date, shares of SYRS have plunged 95.4% compared with the industry’s 3.8% decline.
Image Source: Zacks Investment Research
Based on the disappointing outcome, Syros has decided to stop the HR-MDS study followed by a thorough review of the clinical data to evaluate the next steps. This is a huge setback for the company, leaving SYRS without a pipeline candidate. In the same press release, the company also stated that the failure of the SELECT-MDS-1 study to meet its primary endpoint constitutes an event of default under its secured loan facility with Oxford Finance.
SYRS’ Termination of Mid-Stage Leukemia Study in August
The latest stock price drop marks the second pipeline setback for Syros in around three months. In August 2024, Syros stock plummeted after it discontinued enrollment in the mid-stage acute myeloid leukemia (AML) study of tamibarotene based on poor results from a prespecified interim analysis.
The phase II SELECT-AML-1 study evaluated the triple therapy of tamibarotene in combination with AbbVie’s (ABBV - Free Report) Venclexta (venetoclax) and azacitidine compared with the doublet regimen of Venclexta and azacitidine in newly diagnosed, unfit AML patients with RARα gene overexpression.
The study observed similar CR/CR with incomplete hematologic recovery rates of 65% and 70% between the triplet and doublet arms, respectively. Based on such findings, Syros concluded that the likelihood of the study demonstrating superiority at the final analysis in 80 patients is low, leading to the decision to halt enrollment.
AbbVie’s Venclexta is currently approved in the United States to treat adult patients with chronic lymphocytic leukemia and AML. The drug is also approved in the EU for the same indications under the brand name, Venclyxto.
Allogene Therapeutics’ loss estimates per share have narrowed from $1.40 to $1.35 for 2024 over the past 60 days, while that for 2025 has narrowed from $1.46 to $1.35 per share. ALLO’s shares have lost 15.3% year to date.
Allogene Therapeutics’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%.
Biogen’s earnings estimates have risen from $16.12 to $16.38 per share for 2024 over the past 60 days, while that for 2025 has increased from $17.09 to $17.16. BIIB’s shares have lost 35.9% year to date.
Biogen’s earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 9.99%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
Shares of Syros Pharmaceuticals (SYRS - Free Report) plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, tamibarotene, for treating higher-risk myelodysplastic syndrome (HR-MDS) failed to meet the primary endpoint of complete response (CR) rate. Tamibarotene is Syros’ proprietary, oral, selective RARα agonist.
The phase III SELECT-MDS-1 study evaluated tamibarotene in combination with azacitidine, a chemotherapy, in newly diagnosed HR-MDS patients with RARα gene overexpression. Per the data readout, the CR rate in the first 190 enrolled patients in the tamibarotene/azacitidine treatment arm was 23.8%, which failed to demonstrate statistical significance over the CR rate of 18.8% observed in the placebo/azacitidine control arm.
However, Syros reported that the combo drug was well-tolerated by the total enrolled HR-MDS patient population in the SELECT-MDS-1 study. Moreover, the treatment-related adverse events were similar to those observed in earlier company-sponsored studies.
Year to date, shares of SYRS have plunged 95.4% compared with the industry’s 3.8% decline.
Image Source: Zacks Investment Research
Based on the disappointing outcome, Syros has decided to stop the HR-MDS study followed by a thorough review of the clinical data to evaluate the next steps. This is a huge setback for the company, leaving SYRS without a pipeline candidate. In the same press release, the company also stated that the failure of the SELECT-MDS-1 study to meet its primary endpoint constitutes an event of default under its secured loan facility with Oxford Finance.
SYRS’ Termination of Mid-Stage Leukemia Study in August
The latest stock price drop marks the second pipeline setback for Syros in around three months. In August 2024, Syros stock plummeted after it discontinued enrollment in the mid-stage acute myeloid leukemia (AML) study of tamibarotene based on poor results from a prespecified interim analysis.
The phase II SELECT-AML-1 study evaluated the triple therapy of tamibarotene in combination with AbbVie’s (ABBV - Free Report) Venclexta (venetoclax) and azacitidine compared with the doublet regimen of Venclexta and azacitidine in newly diagnosed, unfit AML patients with RARα gene overexpression.
The study observed similar CR/CR with incomplete hematologic recovery rates of 65% and 70% between the triplet and doublet arms, respectively. Based on such findings, Syros concluded that the likelihood of the study demonstrating superiority at the final analysis in 80 patients is low, leading to the decision to halt enrollment.
AbbVie’s Venclexta is currently approved in the United States to treat adult patients with chronic lymphocytic leukemia and AML. The drug is also approved in the EU for the same indications under the brand name, Venclyxto.
Syros Pharmaceuticals, Inc. Price and Consensus
Syros Pharmaceuticals, Inc. price-consensus-chart | Syros Pharmaceuticals, Inc. Quote
SYRS’ Zacks Rank & Stocks to Consider
Syros currently carries a Zacks Rank #3 (Hold).
Some better-ranked pharma stocks are Allogene Therapeutics (ALLO - Free Report) and Biogen (BIIB - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Allogene Therapeutics’ loss estimates per share have narrowed from $1.40 to $1.35 for 2024 over the past 60 days, while that for 2025 has narrowed from $1.46 to $1.35 per share. ALLO’s shares have lost 15.3% year to date.
Allogene Therapeutics’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%.
Biogen’s earnings estimates have risen from $16.12 to $16.38 per share for 2024 over the past 60 days, while that for 2025 has increased from $17.09 to $17.16. BIIB’s shares have lost 35.9% year to date.
Biogen’s earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 9.99%.